



+43-660.111.89.54



progress-in-medicine.com



austria@progress-in-medicine.com



Information for potential future licensees and operational operators of a treatment centre

1. What is it about

More than 6 years ago, a German graduate engineer, specializing in process engineering / bio chemistry, developed a process for the selective elimination of pathogenic microorganisms (parasites, viruses, worms, etc.) in the human body. Viral diseases, for which there are no effective medication or bacteria, but also amoebae, protozoa as well as worms and also molds become causally treatable.

The treatment of meanwhile far more than 100 patients has shown that the new procedure can be used very successfully with numerous cancer illnesses, as well as with Parkinson and several other illnesses caused by pathogenic microorganisms (among them also Covid-19, Dengue fever, shingles, chicken pox). Parkinson's patients showed no symptoms that could have been indicative of their disease after only 1 month. Tumours and metastases were also reduced or eliminated within a comparatively short time, and the cure for shingles was reduced from weeks or months to just 1 treatment. The possibilities for treatment of other diseases are not yet foreseeable, since with each new patient new findings may emerge. It is also worth mentioning that the new process can also successfully eliminate antibiotic-resistant germs (so-called hospital germs), which could save hundreds of thousands of lives every year.

2. what is our goal

Our goal is, as a future licensor of this new process, to attract partners or licensees who will act as investors and operational operators of treatment centres. These treatment centres could be part of an existing facility (e.g., clinic) or could be operated separately in purpose-built buildings. It should also be noted that patients can be treated on an outpatient basis and the presence of beds is not essential.

Depending on the disease, a treatment unit can last up to 4 hours / day.

3. current status quo

To date, all treatments of patients have taken place in Austria, China and especially in Cuba. One of the reasons for this is also that there is no influence of the pharmaceutical industry in Cuba and therefore the procedure could be practiced without any interference. The inventor / licensor financed all treatments in the last 6 years from his own funds, since patients could not otherwise make any financial contribution, except for occasional gifts in kind. Due to the extraordinary success of the new procedure, the rush of new patients has meanwhile become so great by word-of-mouth propaganda that an admission stop had to be imposed due to the limited space.

A number of discussions are currently being held with potential operators and investors in several countries. The preference is for countries in the Middle East and South America, since these are the least dependent on the pharmaceutical industry and the most willing to accept new alternative treatment options.



+43-660.111.89.54



progress-in-medicine.com



austria@progress-in-medicine.com



Plans are underway to establish a new treatment centre under medical management, which will comprise 100 rooms, with a configuration intended to accommodate both VIP patients and standard patients. In order to bridge the period until the final commissioning of this first centre (duration 12 months) and to give patients on site as well as other interested investors and operational operators the opportunity to either be treated themselves or to refer their own contacts (patients) for treatment, the intention is to set up a treatment option for up to 4 patients / day during the transitional period. By demonstrating clear and quantifiable success in this initiative, the new procedure will be promoted not only in the country of the first treatment centre, but it will also provide additional reassurance to other investors and operators regarding the security of their future activities as licensees.

4. further development (First-Come-First-Serve)

The development and establishment of the new "franchise" (licensor/licensee) structure is currently still influenced by the licensor, as inventor, trainer and organizer in one person (procurement of the necessary technical equipment, other on-site consulting) (bottleneck). It will therefore not be possible to be active in the realization of several projects in several countries at the same time. In the beginning, the focus will be on the realization of the first treatment centre and the certification of the new procedure. We expect that the number of inquiries from other potential licensees will increase significantly thereafter.

The goal will be to establish the new procedure in as many countries as possible.

With the establishment of the first treatment centre, a training facility for operators of new centres is also planned in order to avoid personnel bottlenecks in the further development of the new organizational structure.

For optimal planning of the upcoming procurement measures (technical equipment, aids, staff), it would be desirable if potential investors/operators) would register their interest as future licensees at an early stage and come to a contractual agreement with the licensor. The following applies: first-come-first-served.

5. costs

Investment costs depend on the respective country, on the number of units to be licensed (1 unit for 2 persons/day) and on the question whether the treatment is to take place in an existing facility (clinic) with all its own analysis facilities (such as laboratory, MRI, ultrasound, etc.) or in a new centre to be built.

In addition to license fees to be agreed with the operators, the social aspect should also play a role in the present project. Not only rich patients should be able to afford treatment. It is expected that an additional "donation" (as a % share of the treatment costs), still to be defined in terms of amount, will be paid for the treatment of poorer patients. It is to be left to the licensor to decide, e.g. within the framework of a foundation, on the use of the funds to set up his own centres where indigent patients in countries to be determined can be treated free of charge.



+43-660.111.89.54



progress-in-medicine.com



austria@progress-in-medicine.com



6. **miscellaneous**

Unfortunately, it is not possible to go into all the details of the new treatment and investment options in this letter. This should be reserved for a direct discussion with us, in which, in addition to a financial investor, a medical expert (possibly as the future operator of a centre) should also participate.

Please understand that we assume that in this discussion not only one-sided information should be given, but both sides should communicate what they are able to contribute in a future cooperation.

If you have any questions, please do not hesitate to contact us via our [contact form](#).

Our website <https://www.progress-in-medicine.com> is available for initial brief information.

LIVE BETTER WITH LESS PARASITES

